Literature DB >> 11354234

Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated?

H U Wittchen1, M Höfler, W Meister.   

Abstract

The study examines the prevalence of depressive syndromes among unselected primary care attenders, as well as doctors' recognition and treatment rates, in order to examine patient and doctor-related factors associated with poor recognition. This nationwide study included a total of 20421 patients (aged 15-99 years) attending their primary care doctors (n = 633) on the study's target day in April 1999. Patients received a self-report questionnaire, including the Depression Screening Questionnaire (DSQ), to provide diagnoses of depressive disorders according to the criteria of DSM-IV and ICD-10. Doctors completed: (1) a pre-study questionnaire assessing data on doctors' psychosocial, professional and training background, as well as current practices in patients with depression and (2) an evaluation form for each patient seen to assess his diagnostic decision, clinical severity and treatment choices. Taking the DSQ as a yardstick, 4.2% of all primary care attenders fulfilled criteria for a major depressive episode according to DSM-IV; considerably higher rates of 11.3% were obtained using the ICD-10 criteria for mild depressive episodes. Rates of depression were higher in females, increased by age, and were also elevated in those retired, unemployed as well as non-working housemen/wives. Taking the doctors' decision of definite or probable depression, 75% of all DSM and 59% of all ICD-10 diagnoses were recognized by the treating physician. However, doctors also assigned diagnoses of definite depression in an additional 11.7% of patients not meeting either ICD-10 nor DSM-IV criteria. Among correctly identified depression cases doctors decided to prescribe drug treatments in 72.7% (DSM) and 60.8% (ICD). Some 16.2% of DSM and 10.1% of ICD-cases were referred to mental health specialists; non-drug interventions were prescribed for 19.8% (DSM) and 24.9% (ICD), respectively. Multiple logistic regression analyses revealed that recognition is associated with prior treatment episodes, increasing number of depression symptoms, patients higher age, practice experience of treating physician greater 5 years and psychomotor retardation. These findings confirm the high prevalence of depressive syndromes in primary care settings and underline the particular challenge posed by a high proportion of with near-threshold symptomology patients. Although recognition rates among more severe major depressive patients as well as treatments prescribed appear to be more favourable than in previous studies, the situation in less severe cases, and the high proportion of doctors' definite depression diagnoses in patients with depression symptoms that are clearly below even the subthreshold level, raises significant concerns.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11354234     DOI: 10.1097/00004850-200105000-00001

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  41 in total

1.  Psychiatric caseness is a marker of major depressive episode in general practice.

Authors:  Søren Dinesen Ostergaard; Leslie Foldager; Christer Allgulander; Alv A Dahl; Marja-Terttu Huuhtanen; Ib Rasmussen; Povl Munk-Jørgensen
Journal:  Scand J Prim Health Care       Date:  2010-07-13       Impact factor: 2.581

2.  Beliefs and attitudes of French family practitioners toward depression: the impact of training in mental health.

Authors:  Joanna L Norton; Christelle Pommié; Joël Cogneau; Mark Haddad; Karen A Ritchie; Anthony H Mann
Journal:  Int J Psychiatry Med       Date:  2011       Impact factor: 1.210

3.  Knowledge and Attitudes Towards Clinical Depression among Community Medical Providers in Gujarat, India.

Authors:  Daniella A Loh; Amul Joshi; Kanako Taku; Nathaniel Mendelsohn; Craig L Katz
Journal:  Psychiatr Q       Date:  2018-06

4.  Identification of major depressive disorder among the long-term unemployed.

Authors:  Kirsti Nurmela; Aino Mattila; Virpi Heikkinen; Jukka Uitti; Aarne Ylinen; Pekka Virtanen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-11-09       Impact factor: 4.328

5.  Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study.

Authors:  Hans-Ulrich Wittchen; Sabine M Apelt; Gerhard Bühringer; Markus Gastpar; Markus Backmund; Jörg Gölz; Michael R Kraus; Felix Tretter; Jens Klotsche; Jens Siegert; David Pittrow; Michael Soyka
Journal:  Int J Methods Psychiatr Res       Date:  2005       Impact factor: 4.035

6.  Aims, design and methods of the Smoking and Nicotine Dependence Awareness and Screening (SNICAS) study.

Authors:  Stephan Muehlig; Eva Hoch; Michael Hoefler; David Pittrow; Hans-Ulrich Wittchen
Journal:  Int J Methods Psychiatr Res       Date:  2003       Impact factor: 4.035

7.  The role of gender and anxiety in the association between somatic diseases and depression: findings from three combined epidemiological studies in primary care.

Authors:  E Asselmann; J Venz; L Pieper; H-U Wittchen; D Pittrow; K Beesdo-Baum
Journal:  Epidemiol Psychiatr Sci       Date:  2017-11-09       Impact factor: 6.892

8.  Screening for depression in the older long-term unemployed.

Authors:  Iris Liwowsky; Dietmar Kramer; Roland Mergl; Anke Bramesfeld; Antje-Kathrin Allgaier; Ernst Pöppel; Ulrich Hegerl
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-12-01       Impact factor: 4.328

9.  Comparison of two self-rating scales to detect depression: HADS and PHQ-9.

Authors:  Maja Hansson; Jayanti Chotai; Annika Nordstöm; Owe Bodlund
Journal:  Br J Gen Pract       Date:  2009-09       Impact factor: 5.386

10.  Mental disorders in primary care in Israel: prevalence and risk factors.

Authors:  Neil Laufer; Nelly Zilber; Pablo Jecsmien; Binyamin Maoz; Daniel Grupper; Haggai Hermesh; Royi Gilad; Abraham Weizman; Hanan Munitz
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-01-04       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.